SCLC Tarlatamab Blood Collection
ConditionSmall-cell Lung Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDuke University
About this trial
The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting.
The investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.
Eligibility criteria
Qualifiers
Pathologically documented small cell lung cancer (SCLC) or neuroendocrine tumor
Appropriate candidate for treatment with tarlatamab based on investigator discretion
Age > 18 years
Signed written informed consent including HIPAA according to institutional guidelines
Disqualifiers
Does not meet all inclusion criteria
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov